Digital Storytelling in Pediatric Safe Drug

May 4, 2023 updated by: Şeyda BİNAY YAZ, Ege University

The Efficiency of Education Given to Students With Digital Storytelling in Safe Pediatric Intravenous Drug Administration

Summary Aim: This research was conducted to determine the effectiveness of education given to students using digital storytelling in safe pediatric intravenous drug administration.

Method: It is a randomized controlled experimental study. The sample of the study consisted of 84 nursing students. The students included in the study were divided into two equal groups: the experimental and control groups. Digital education material of the experimental group and theoretical education was applied to the control group. Before and after the training, a post-knowledge test was made and evaluated.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

84

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • İzmir, Turkey, 35665
        • Semih

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Being a student of the Department of Nursing
  • Taking the child health and diseases nursing course and being successful
  • Volunteering to participate in the research

Exclusion Criteria:

  • Participate and quit the study
  • Being a 1st and 2nd year nursing student
  • Failure of the child health and diseases nursing course

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Digital Education Group

All participants in this group were given the "Safe pediatric intravenous drug administration knowledge test" prepared by the researchers as a pre-test.

The participants of this group, who were determined by randomization, were given training prepared using the digital storytelling method. The training took 25 minutes.

After the training, the "Safe intravenous drug administration knowledge test" was applied as a post-test.
Other: Digital Education Group
Providing training on safe pediatric intravenous drug administration with digital storytelling method
No Intervention: Control Group

No intervention was made. All participants in this group were given the "Safe pediatric intravenous drug administration knowledge test" prepared by the researchers as a pre-test.

Afterward, theoretical information on the subject was given. After theoretical information, the "Safe intravenous drug administration knowledge test" was applied as a post-test.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Statistical difference between groups about knowledge test scores
Time Frame: During the education, approximately 25 minutes

Safe pediatric drug practices knowledge test is applied twice as pre-test and post-test in experimental and control groups.

Safe pediatric drug practices knowledge test: It is a 17-question form prepared by researchers. Content validity has been made for the form. Each correct answer is calculated as 1 point and each wrong answer is calculated as 0 points. The higher the score obtained from the questionnaire, the higher the level of knowledge.
During the education, approximately 25 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ege University

Collaborators

Izmir Bakircay University

Investigators

  • Principal Investigator: Semih Akkoyun, Izmir Bakircay University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 8, 2021

Primary Completion (Actual)

April 30, 2022

Study Completion (Actual)

April 6, 2023

Study Registration Dates

First Submitted

April 17, 2023

First Submitted That Met QC Criteria

May 4, 2023

First Posted (Estimate)

May 5, 2023

Study Record Updates

Last Update Posted (Estimate)

May 5, 2023

Last Update Submitted That Met QC Criteria

May 4, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • Bakircay

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The study will be prepared for publication

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe